The long data timeline (H2 2029) limits near-term catalysts, but the deal expands Tarsus' retina pipeline with a potentially blockbuster orphan drug. Watch for HSR clearance and any competitive Stargardt pipeline updates; near-term stock movement likely driven by financing details and investor reception of the upfront cash/stock mix.
Drug in focus
TARS drug pipeline →ALK-001
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If the Phase 3 NORTHSTAR trial succeeds, potential FDA approval would likely follow in 2030 or later, given topline data is not expected until H2 2029.
- Next catalyst
- None dated
What to watchALK-001 has no near-term binary catalyst, the Phase 3 NORTHSTAR topline readout is not expected until H2 2029. TARS stock will be driven primarily by XDEMVY commercial execution and nearer-term pipeline catalysts (TP-04, TP-05) over the next 12 months. Monitor the Alkeus acquisition close and any early NORTHSTAR enrollment updates, but do not trade TARS on ALK-001 expectations alone.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $65.33entry
- T+1 · 3mo ago −0.83%α −1.44% · $64.79
- T+5 · 3mo ago +5.43%α +4.22% · $68.88
- T+20 · 3mo ago +27.36%α +26.76% · $83.21
- T+60 · 18d ago +14.57%α +16.24% · $74.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tarsus acquires Alkeus Pharmaceuticals for $450M upfront plus up to $350M in milestones, adding the Phase 3 Stargardt disease candidate gildeuretinol (ALK-001). The deal weds a promising but early-stage asset with no approved therapy today against Tarsus' existing retina capabilities, and top-line data is not expected until H2 2029. The acquisition is accretive to Tarsus' pipeline but adds significant execution risk and a long timeline.
Key Financial Metrics
Key Facts
- Upfront consideration: ~$450 million ($270M cash + $180M Tarsus common stock at $61.38/share).
- Milestones: up to $350 million upon regulatory approval and first commercial sale.
- Royalties: low single-digit tiered descending on gildeuretinol net sales.
- Phase 3 NORTHSTAR trial (enrolling ~230 patients) topline data expected H2 2029.
- Stargardt disease has ~36,000 clinically diagnosed patients in the U.S. with no FDA-approved therapy.
- Gildeuretinol has Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations.
- TEASE-1 data: 29.5% slower annualized growth rate of atrophic lesions (p<0.001) vs untreated arm; 87% less likely to experience significant low-light vision loss.
- Transaction approved by both boards and Alkeus stockholders; expected to close in 2026.
- Tarsus' pipeline includes XDEMVY (approved), TP-04 (Phase 2), TP-05 (Phase 2), and IRX-101 (Phase 2).
Financial Impact
$450M upfront plus up to $350M in regulatory/milestone payments; low single-digit royalties on net sales
Risk Factors
- Phase 3 failure risk (Stargardt trials are notoriously difficult to read on endpoints)
- Dilution from ~$180M stock issuance (2.93M shares at $61.38, ~6% of current shares outstanding if pre-money ~48M shares)
- Long timeline (H2 2029) with no near-term revenue from gildeuretinol
- Integration risk and cash burn ($270M upfront depletes Tarsus' cash reserves)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340125 |
Track record
21 reports on TARS
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers